Prime Medicine, Inc.

NasdaqGM:PRME Stock Report

Market Cap: US$401.9m

Prime Medicine Management

Management criteria checks 2/4

Prime Medicine's CEO is Keith Gottesdiener, appointed in Jul 2020, has a tenure of 4.5 years. total yearly compensation is $5.40M, comprised of 11.6% salary and 88.4% bonuses, including company stock and options. directly owns 3.42% of the company’s shares, worth $13.74M. The average tenure of the management team and the board of directors is 2.5 years and 3.1 years respectively.

Key information

Keith Gottesdiener

Chief executive officer

US$5.4m

Total compensation

CEO salary percentage11.6%
CEO tenure4.5yrs
CEO ownership3.4%
Management average tenure2.5yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

Dec 19
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

Nov 26

Prime Medicine's Promising Pipeline: PM359 And Cash Burn Concerns

Sep 04

Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Situation

Sep 04
Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Situation

Prime Medicine Stock: Only For The Most Patient Of Investors

Jun 20

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?

May 14
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Jan 28

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

Aug 25
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Rate

May 12
We're Not Very Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Rate

Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?

Jan 24
Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?

CEO Compensation Analysis

How has Keith Gottesdiener's remuneration changed compared to Prime Medicine's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$219m

Jun 30 2024n/an/a

-US$217m

Mar 31 2024n/an/a

-US$204m

Dec 31 2023US$5mUS$625k

-US$198m

Sep 30 2023n/an/a

-US$173m

Jun 30 2023n/an/a

-US$158m

Mar 31 2023n/an/a

-US$151m

Dec 31 2022US$924kUS$542k

-US$142m

Sep 30 2022n/an/a

-US$171m

Jun 30 2022n/an/a

-US$158m

Mar 31 2022n/an/a

-US$126m

Dec 31 2021US$3mUS$524k

-US$184m

Sep 30 2021n/an/a

-US$118m

Dec 31 2020US$935kUS$252k

-US$5m

Compensation vs Market: Keith's total compensation ($USD5.40M) is above average for companies of similar size in the US market ($USD2.14M).

Compensation vs Earnings: Keith's compensation has increased whilst the company is unprofitable.

CEO

Keith Gottesdiener (70 yo)

4.5yrs

Tenure

US$5,403,071

Compensation

Dr. Keith Michael Gottesdiener, Ph D, serves as Venture Partner at Samsara Biocapital, LLC. He serves as the President & Secretary at Prime Medicine, Inc and also serves as a Director and Chief Executive O...

Leadership Team

NamePositionTenureCompensationOwnership
Keith Gottesdiener
President4.5yrsUS$5.40m3.42%
$ 13.7m
Ann Lee
Chief Technical Officer3.3yrsUS$2.26m0%
$ 0
Jeremy Duffield
Chief Scientific Officer4yrsUS$2.26m0.76%
$ 3.0m
Andrew Anzalone
Co-Founder & Head of Prime Editing Platformno datano datano data
David Liu
Co-Founder & Member of Scientific Advisory Boardno datano data15.8%
$ 63.5m
Allan Reine
Chief Financial Officer1yrno datano data
Meredith Goldwasser
Senior VP and Head of Strategy & Corporate Operations4.3yrsno datano data
Carman Alenson
Senior VP of Finance & Chief Accounting Officer2.3yrsno datano data
Karen Brown
Senior Vice President of Intellectual Property & Legal Affairsno datano datano data
Niamh Alix
Chief Human Resources Officer2.5yrsno datano data
Richard Brudnick
Chief Business Officer2.5yrsUS$1.67mno data
Fubao Wang
Senior VP & Head of Regulatory Affairs2.5yrsno datano data

2.5yrs

Average Tenure

57yo

Average Age

Experienced Management: PRME's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Keith Gottesdiener
President4.5yrsUS$5.40m3.42%
$ 13.7m
David Liu
Co-Founder & Member of Scientific Advisory Board2.4yrsno data15.8%
$ 63.5m
Robert Taylor Nelsen
Independent Director4.3yrsUS$445.46k0.013%
$ 50.6k
Michael Kelly
Independent Director3.2yrsUS$454.46k0%
$ 0
Kaye Foster-Cheek
Independent Director3.1yrsUS$451.46k0%
$ 0
David Schenkein
Independent Director5.3yrsUS$455.46kno data
Guangping Gao
Member of Scientific Advisory Board2.4yrsno datano data
Wendy Chung
Independent Director3.2yrsUS$451.96k0%
$ 0
Yvonne Chen
Member of Scientific Advisory Board2.4yrsno datano data
Thomas Cahill
Independent Director3.2yrsUS$451.96kno data
Agnieszka Czechowicz
Member of Scientific Advisory Board2.4yrsno datano data
James Haber
Member of Scientific Advisory Board2.4yrsno datano data

3.1yrs

Average Tenure

64yo

Average Age

Experienced Board: PRME's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/27 02:06
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Prime Medicine, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Konstantinos BiliourisBMO Capital Markets Equity Research
Yevgeniya LivshitsChardan Capital Markets, LLC
Samantha Lynn SemenkowCitigroup Inc